Success stories of triterpenoid-based hybrid molecules as new promising anticancer agents: Triterpenoid-driven analogs

Abstract

Natural product-based hybrid molecules have recently revolutionized promising anticancer results. Triterpenoids represent a wide-spread class of secondary metabolites with a carbon skeleton which contains six isoprene units by the cyclization of squalene. Molecular optimization is frequently necessary for improvement on target specificity, lower toxicity, potency, and stability as well. Lately, to improve the molecular potency some synthetic toolboxes which can access the molecular diversity have been developed. This review showcases structural modification of triterpenoids and their anti-cancer efficacy compared to original compounds.